Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

This study is testing a new type of CAR-T cell therapy — an advanced immune cell treatment where a patient's own T cells are genetically engineered to attack cancer — in children with relapsed or treatment-resistant B-cell blood cancers including leukemia (B-ALL) and lymphoma. **You may be eligible if...** - You are between 6 months and 18 years old - You have been diagnosed with CD19-positive B-cell leukemia or lymphoma that has come back or has not responded to standard treatments - You have not achieved remission despite chemotherapy, or your cancer came back after a stem cell transplant **You may NOT be eligible if...** - You have active, serious infections that cannot be controlled - You have significant organ dysfunction (heart, liver, or kidney) - You have a condition that would make the CAR-T treatment unsafe Talk to your doctor to see if this trial is right for you.